MindMed sets milestone in finding psychedelic cure for opioid addiction

The company has come up with a derivative of ibogaine, a psychoactive substance from an African shrub.


Awakn Life Sciences starts study on ketamine treatment for gambling addiction

Toronto-based biotechnology company Awakn has a research program on ketamine-assisted psychotherapy against multiple addictions.


Growing body of research shows patients with addiction, PTSD, and depression can benefit from psychedelic substances

Numinus Wellness chief medical officer Dr. Evan Wood cautions that it’s not a cure for everybody—but trials have shown statistically significant results